NEJM basically described year-old Mustang Bio data, STAT's Feuerstein says
STAT's Adam Feuerstein tweeted, "$MBIO - Y'day's 'bubble boy' gene therapy hullabaloo was news-ish. Basically, the NEJM paper describes same data presented one year ago. Approx. 4 months of added follow up." Shares of Mustang Bio are up 163%, or $4.34, to $7.00 in premarket trading after the company announced last night that the New England Journal of Medicinepublished data from St. Jude Children's Research Hospital. The data comes from a Phase 1/2 clinical trial of a lentiviral gene therapy for the treatment of newly diagnosed infants under two years old with XSCID, also referred to as SCID-X1 and commonly known as bubble boy disease, the company said in a statement. Under a licensing agreement with St. Jude, Mustang will develop the lentiviral gene therapy for commercial use as MB-107.